NCT04277741

Brief Summary

The primary objective of the current proposal is to determine the effectiveness of long-term consumption of Fibersym® RW for improving blood lipids (including cholesterol) and body composition. The overall goal of this clinical research is to determine the potential effects that RS4 consumption may have on the prevention of obesity and obesity-related diseases. Fiber in the form of RS4 will be used for the proposed study, given that fiber has been shown to have many beneficial effects on modifiable risk factors associated with obesity-related diseases. Using a long-term randomized-controlled intervention design, blood lipids (total cholesterol, LDL-c, HDL-c, triglycerides) and body composition will be assessed. The investigators anticipate reductions in cholesterol and body fat percentage following 8-weeks of Fibersym® RW consumption.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 18, 2020

Completed
Same day until next milestone

Study Start

First participant enrolled

February 18, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 20, 2020

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
Last Updated

October 4, 2023

Status Verified

October 1, 2023

Enrollment Period

3.4 years

First QC Date

February 18, 2020

Last Update Submit

October 2, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in plasma lipids

    Total cholesterol (TC), LDL-c , VLDL-c, HDL-c , triglycerides (TG) from blood sample in a fasted state

    Week 0, 4, and 8

Secondary Outcomes (3)

  • Change in body composition

    Week 0, 4, and 8

  • Change in BMI

    Week 0, 4, and 8

  • Change in homeostatic model assessment for insulin resistance (HOMA-IR)

    Week 0,4, and 8

Study Arms (2)

Resistant starch bar

EXPERIMENTAL

The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW.

Dietary Supplement: RS4 bar

Native wheat bar

ACTIVE COMPARATOR

The control group will consume one native wheat starch bar per day.

Dietary Supplement: Control bar

Interventions

RS4 barDIETARY_SUPPLEMENT

The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW containing 20g fiber.

Resistant starch bar
Control barDIETARY_SUPPLEMENT

The control group will consume one native wheat starch bar per day.

Native wheat bar

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • BMI ≥ 23 kg/m2
  • elevated to borderline-high LDL-cholesterol (116-159 mg/dL)

You may not qualify if:

  • known allergy to wheat or gluten
  • currently taking medication for chronic disease including anti-inflammatory, anti-hypertensive, lipid lowering, glucose controlling, or steroidal medications
  • taking any supplements that may affect metabolism
  • having anemia or a history of anemia
  • current smoker or a user in the past three months
  • currently pregnant or lactating/planning to become pregnant during the intervention
  • having elevated blood pressure (≥130mmHg/≥80mmHg)
  • presence of diagnosed diabetes mellitus, inflammatory disease, atherosclerotic disease, or other relevant chronic conditions that may affect metabolic processes
  • total cholesterol ≥ 240mg/dL.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Physical Activity and Nutrition Clinical Research Consortium

Manhattan, Kansas, 66502, United States

Location

MeSH Terms

Conditions

HypercholesterolemiaOverweightObesity

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Sara Rosenkranz, PhD

    Kansas State University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
The participant will be blind to the condition that they are in.
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 18, 2020

First Posted

February 20, 2020

Study Start

February 18, 2020

Primary Completion

June 30, 2023

Study Completion

June 30, 2023

Last Updated

October 4, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations